Iron overload and chronic liver diseases;Surcharges en fer et maladies chroniques du foie

Revue du Praticien

Volumn 56, Issue 19, 2006, Pages 2130-2134

  Abergel, Armand ^a   Ruivard, Marc ^b   Bonny, Corinne ^a  

^a Centre d'Hépato gastroentérologie   (Germany)

^b Service de Médecine Interne   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN;

ALCOHOLIC FATTY LIVER; CARCINOGENESIS; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; FATTY LIVER; FIBROGENESIS; GENE MUTATION; HEMOSIDEROSIS; HUMAN; INFLAMMATION; IRON OVERLOAD; NECROSIS; PORPHYRIA CUTANEA TARDA; REVIEW; TRANSFERRIN BLOOD LEVEL; VIRUS HEPATITIS;

CHRONIC DISEASE; CLINICAL TRIALS; FATTY LIVER; FERRITINS; HEPATITIS, VIRAL, HUMAN; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; METABOLIC SYNDROME X; PHLEBOTOMY; PORPHYRIAS;

EID: 33846067752     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Fletcher L, Halliday J, Powell L. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol 1999;14:202-14.
2. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005;25:461-72.
3. Harrison-Fidik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006;281:22974-82.
4. Ioannou G, Dominitz J, Weiss N, et al. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 2004;126:1293-301.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
6. Moirand R, Mortaji AM, Loreal O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-7.
7. Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005;28:2061-3.
8. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179-87.
9. Sulieman M, Asleh R, Cabantchik ZI, et al. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 2004;27:2730-2.
10. Tung BY, Emond MJ, Bronner MP, et al. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-26.
11. Aoki CA, Rossaro L, Ramsemooj D, et al. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005;39:71-4.
12. Fontana RJ, Israel J, Leclair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter randomized controlled trial. Hepatology 2000;31:730-6.
13. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter prospective randomized controlled trial. Hepatology 2000;32:135-8.